Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

(2018) Karin Rådholm et al.   CIRCULATION

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

(2017) Javed Butler et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

(2017) James L. Januzzi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial

(2016) Atsushi Tanaka et al.   Cardiovascular Diabetology

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk

(2016) Benjamin M. Scirica et al.   JAMA Cardiology

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE